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OVERVIEW — This issue brief reviews the evolution of the disease manage-
ment model and the ways it relates to care coordination and case management
approaches. It also looks at examples of population-based disease management
programs operating in both the private and public sectors and reviews the
evidence of their success. Finally, the paper considers the policy implications
of adapting this model to a Medicare fee-for-service population.
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Disease Management to
Population-Based Health:
Steps in the Right Direction?
“Disease management,” raised as a potential beacon in an otherwise
gloomy landscape, has become a catchphrase in health policy circles.
Widely heralded as a means to both control cost and improve quality,
disease management programs abound in the private sector. Now many
people are calling on Medicare to follow the lead of some state Medic-
aid programs in incorporating disease management principles into broad
public programs.
SHAPING THE CONCEPT
Disease management grew from attention to the truism that 20 percent
of the patients in a given population will account for 80 percent of the
costs. If this category of patients can be treated more appropriately and
persuaded to comply more fully with the treatment regimen, the think-
ing runs, health outcomes will be improved and money saved. (It should
be noted that the 20 percent is not a static population, as some people
with chronic conditions develop complications and move into the high-
cost category, while others stabilize or die.)
While “disease management” can refer to a wide range of services, the
Disease Management Association of America (DMAA), the industry trade
association, proffers this definition:
Disease management is a system of coordinated healthcare interventions
and communications for populations with conditions in which patient
self-care efforts are significant. Disease management:
■ supports the physician or practitioner/patient relationship with a
plan of care,
■ emphasizes prevention of exacerbations and complications utiliz-
ing evidence-based practice guidelines and patient empowerment strat-
egies, and
■ evaluates clinical, humanistic, and economic outcomes on an ongo-
ing basis with the goal of improving overall health.
Disease management focuses on chronic conditions, most commonly those
affecting large numbers of beneficiaries, such as diabetes or congestive
heart failure (CHF). Some programs also target rare but high-cost con-
ditions, such as hemophilia and sickle-cell anemia. The philosophy in
either case is to facilitate effective interventions as early as possible in
the course of the disease.
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Chronic care accounts for an increasing share of Americans’ health care
needs. An estimated 125 million Americans have one or more chronic
conditions; half of this group have multiple conditions.1 Chronic condi-
tions cut across all age groups, though they are especially prevalent among
the elderly. Disease management is one effort to shift from health care’s
traditional acute-care orientation.
Well-designed disease management comports well with the chronic care
model (CCM) proposed by leading researcher Edward Wagner, M.D., and
widely accepted as a touchstone. The CCM integrates community and
health plan resources to facilitate productive interactions between an in-
formed, activated patient and a prepared, proactive practice team. Im-
portant elements are support for patient self-management, reliance on
evidence-based guidelines or decision-support tools, delivery system re-
design, and investment in clinical information systems.
Disease management sometimes is used interchangeably with “care co-
ordination” or “case management.” Distinctions among the labels are by
no means clear-cut. A study by Mathematica Policy Research for the Health
Care Financing Administration (now the Centers for Medicare and Med-
icaid Services, or CMS) cast disease management and case management
as the two subsets of care coordination. More recently, Barbara Cooper
and Eliot Fishman, writing for the Partnership for Solutions, used “care
management” as the summary category, suggesting that “Care-manage-
ment services can range from a care manager simply reminding people
to take their medicines to figuring out what care they need (assessment
and care planning), helping them to get it (coordination), and making
sure it is working (monitoring).”2
All of these concepts have in common the principle of getting a person
clinically appropriate care in a timely manner without wasting resources.
Care coordination seeks primarily to help a patient navigate the system,
working across care settings and providers and frequently accessing other
services, such as personal care or community programs, as well. Case
management also incorporates the organization of benefits and services
across multiple providers. It tends to be event-driven—a patient has an
accident, is diagnosed with an additional comorbidity, or some similar
trigger—and tailored to individual patients whose cases are expected to
be high in cost or complexity. In fact, high-cost case management was a
precursor to disease management, applied at the individual level.
Today’s disease management is population-based; that is, its practitio-
ners accept responsibility for the health outcomes and utilization of all
members of a targeted group (such as health plan enrollees with a trig-
gering diagnosis), not just those individuals who may seek treatment
during a given period. Different interventions are targeted to different
categories of patients, according to the severity of the condition and other
risk factors. Population-based disease management (PDM)3 typically in-
terfaces with one primary physician per patient and, relying on a clinical
Today’s disease man-
agement is population-
based.
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evidence base related to a particular condition or set of conditions, fo-
cuses on patient and physician education and adherence to a care plan.
Disease management vendors sometimes market case-management ser-
vices separately from their disease-management services or call on case
management services already in place in a health plan for complicated
cases. One reason for separating the two is that case-management liabil-
ity may be higher. PDM administrators stress that their programs are
designed to augment and complement the care provided by a participant’s
physician, but not to provide (or advocate for) additional categories of
service or to assume clinical responsibility apart from the physician.
Some health plans and employers use the disease management desig-
nation for what others might call a wellness program. Smoking cessa-
tion, weight loss, and stress management are behavior modifications
that can reasonably be associated with better health outcomes and lower
utilization of services. For example, Caterpillar has reported that its
Healthy Balance program, focused on weight management, has pro-
duced lower health risk scores for employees and lower average claim
costs to the company.4
THE GROWTH OF AN INDUSTRY
Pharmaceutical companies were among the first to experiment with dis-
ease management approaches. As Thomas Bodenheimer described in a
1999 New England Journal of Medicine article, the expansion of managed
care in the 1990s meant that pharmaceutical manufacturers could no
longer simply promote their products in visits to physicians’ offices.5 In
order for the manufacturer to make a sale, the physician had to pre-
scribe a drug, the health maintenance organization (HMO) or pharmacy
benefit manager (PBM) had to cover it, and the patient had to take it.
Typically targeted to a health plan, disease management was a strategy
to influence all these transactions and thus gain more control over de-
mand. Some PBMs, with access to prescription data enabling them to
identify patients with a wide range of conditions, developed their own
disease management programs and marketed them to employers as part
of a package of services.
These early versions of disease management had an arm’s-length qual-
ity, consisting primarily of booklets and brochures designed to alert
and educate patients about a targeted condition. Mailed to new enroll-
ees or made available in physicians’ offices, the written materials left
any next steps to the patient.
A different approach was taken by Medicare’s peer review organiza-
tions (PROs, known today as quality improvement organizations, or
QIOs) when they were charged in the early 1990s with “helping provid-
ers to improve the mainstream of care.”6 From 1992 forward, PROs
worked with hospitals and physicians on quality-improvement projects
Pharmaceutical com-
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focused on specified clinical conditions; among these have remained
diabetes and heart failure.
The mid-1990s saw the emergence of disease management organiza-
tions (DMOs), typically organized around a particular disease state. As
characterized by Robert E. Stone, executive vice president of DMO
American Healthways and president of DMAA, a common strategy for
health plans at this stage was to try to assemble a group of contractors
on a disease-by-disease basis.7 Beneficiaries diagnosed with diabetes
would be enrolled with Contractor A, those with asthma with Contrac-
tor B, and so on. What this approach failed to take into consideration
was that persons with any chronic diagnosis very frequently have more
than one. It was thus possible for a person to be enrolled in multiple
disease management programs, with multiple care managers making
multiple calls to (probably) exasperated physicians. The employer ulti-
mately paying for these services would have found it very difficult to
discern who was responsible for patient outcomes, good or bad.
Some health plans elected to develop their own in-house disease man-
agement capabilities. The most favorable development climate seemed
to be the closed-panel HMO, in which the concept of accountability for
delivering health care to a population was endemic. Kaiser Permanente,
for example, developed a program featuring interdisciplinary care teams
geared to address the clinical, behavioral, and social issues facing its CHF
patients. Through its Care Management Institute, Kaiser has developed a
network of physicians and other clinicians to help educate their peers
and implement evidence-based medicine into everyday practice.8 Other
insurers, especially those with more loosely structured network-based
plans among their offerings, have opted to contract with one or more
outside vendors for their disease management services.
Whether contracted or homegrown, disease management has prolifer-
ated rapidly. In survey data published in July 2002, Hewitt Associates
found that 76 percent of large employers currently offered some type of
disease management program, most commonly through their health
plans. Some have found that designing their own programs better serves
their needs. Lockheed Martin Aeronautics reported that a disease man-
agement program for diabetic patients run out of an onsite clinic real-
ized savings of more than $600,000 in reduced sick time usage in its first
year of operation.9
Growth has been accompanied by further development. Within a few
years, leading DMOs had refined their model, giving rise to what may
already be described as second-generation disease management. Figure
1 illustrates some of the key transitions from disease management to
population-based health care.
A priority for PDM managers has been developing a mechanism for iden-
tifying the members who will benefit most (and demonstrate the most
financial return) from population-based care programs. The approaches
Whether contracted or
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have evolved over the last few years from programs using only a diag-
nosis of a chronic illness, to those that added additional utilization cri-
teria to the diagnosis, then to predictive modeling solutions.10 Predic-
tive modeling is a new approach to identifying which patients are most
in need of attention and which have the most potential for poor health
outcomes and high costs over the following six months, one year, or
longer. Predictive accuracy depends on the model’s sensitivity to the
data fed into it and the variety and quality of that data, among which
may be claims, pharmacy records, laboratory results and other diagnos-
tic indicators, and information from the health assessments that may be
conducted by a PDM program at the time of enrollment. Some models
use artificial intelligence and “neural networks” to enable them, in ef-
fect, to learn from their own experience.
A health plan sponsor who undertakes to purchase a PDM component
typically contracts to pay a per-member-per-month fee for a package of
PDM services such as patient and provider education, support for pa-
tient self-management, and reminders and alerts. The PDM contractor
agrees to specified performance guarantees, expressed in terms of cost
savings and (sometimes) health outcome measures. Commonly, fees are
at risk, that is, will be forfeit if performance guarantees are not met.
This does not mean that the contractor is obliged to absorb any added
patient treatment costs. In this, they differ from providers in a capitated
system, who are at risk for excess treatment costs. PDM vendors express
little interest in assuming such clinical risk and the insurance functions
(and regulations) that go with it.
To
Ability to provide services across mul-
tiple chronic conditions
Use of sophisticated computer models
that permit the identification of those at
varying levels of risk now and in the
future
Automatic enrollment with opportunity
for beneficiary to opt out
From
Concentration on one particular
disease state
Identification of potential participants
through retrospective claims analysis,
that is, those who have already been
treated for the disease
Recruitment via beneficiary “opt-in,”
that is, beneficiary must take action to
enroll
FIGURE 1
Disease Management to Population-Based Health:
Some Key Transitions
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In addition to fees, plan sponsors may offer bonuses for performance
beyond the guarantee. Some PDM programs have established a track
record sufficient to win them risk-free contract renewals.
BETTER OUTCOMES AND LOWER COSTS:
WHAT IS THE EVIDENCE?
A mantra that PDM programs share with other health care innovators is
that better quality leads to lower cost. Their citations are instinctively
appealing to most listeners: duplications are avoided, hospitalizations
reduced, and expensive and drastic procedures such as amputations pre-
cluded by preventive regimens. In the chronic conditions most likely to
be tapped for PDM (asthma, CHF, chronic obstructive pulmonary dis-
ease, coronary artery disease, and diabetes), analysis has shown ample
room for improvement in both quality and cost.
Evaluation of PDM programs and of the model itself is thus a two-pronged
proposition: Does it produce better outcomes? and Does it generate savings?
There is some ambiguity on both sides.
PDM industry representatives have taken steps to promote measurement
standards that will permit plan-to-plan comparisons of health outcomes.
In February 2003, American Healthways and the Johns Hopkins Outcomes
Verification Program published “Standard Outcome Metrics and Evalua-
tion Methodology for Disease Management Programs.”11 These organi-
zations hope to see the standards contained in this consensus report widely
adopted, though some in the field have suggested that their product is at
best a good start. Many PDM plans have sought accreditation/certifica-
tion by the same accrediting bodies that assess health plan quality—the
National Committee for Quality Assurance, the Joint Commission on
Accreditation of Healthcare Organizations, and the American Accredita-
tion HealthCare Commission, more commonly known as URAC.
A body of peer-reviewed literature on PDM is accumulating, including a
number of randomized controlled studies. Ronald Aubert and colleagues
found significant decreases in fasting glucose levels among patients who
were provided with the services of a nurse case manager who was also a
certified diabetes educator. These patients also reported perceived im-
provement in their health status more than twice as often as their control-
group counterparts. The study did not address cost.12 Researchers at
Geisinger Health Plan found that patients who chose to enroll in its dia-
betes management program had higher scores on diabetes-related HEDIS
(Health Plan Employer Data and Information Set) performance measures
and lower average monthly claims. Inpatient days per patient per year
were lower, though there were more primary care visits.13
CHF programs have been most often studied, with varying results.
For example, Michael Rich and colleagues found that a nurse-directed
multidisciplinary intervention program reduced net cost of care an
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average of $153 per patient per month for the treatment group versus the
control group. Readmissions in the control group were nearly double
that of the treatment group, though survival for 90 days without readmis-
sion, the primary outcome measure, was not significantly different.14 An
interactive home monitoring program studied by Nihir Shah and col-
leagues, on the other hand, produced a significant reduction in cardio-
vascular hospitalizations.15 In a systematic review of 11 CHF studies, Finlay
McAlister and colleagues concluded that specialized follow-up by a
multidisciplinary team led to a substantial reduction in the risk of hospi-
talization, whereas trials employing telephone contact with improved
coordination of primary care services failed to find significant benefit.16
One theme that emerges from a literature review is that, even where
PDM is shown to be effective, no one is altogether sure why. As McAlister
observed, “our interpretation of these trials and the disease manage-
ment programs that were used is hampered by the imprecise descrip-
tions of the interventions and by the lack of data to determine the incre-
mental benefits of each intervention.”17 That is, in a bundle of educa-
tional, support, and monitoring services, what is the weight (or worth)
of each separate component?
This question has cost as well as quality implications. As Rich wrote in
the article referenced above,
Because of the multidisciplinary nature of the intervention, we are un-
able to say which elements were most important in reducing readmis-
sion rates and improving the quality of life. To do so is important from
the perspective of cost, since the elimination of any unnecessary features
could result in further cost savings.
The contractual details of performance guarantees and results achieved
are considered proprietary, so it is difficult to establish prevailing savings
levels. Demonstrating savings is an ongoing challenge for PDM managers
themselves, as witness session titles at virtually every disease management
conference convened. Measurement issues include the following:
■ Group composition. New enrollments in a health plan, disenrollments,
and deaths all change the population being studied over the course of
the measurement period. Accurate identification and stratification of
those with a condition or conditions or at risk in the future remains
challenging.
■ Disease progression. Some chronic diseases, by their nature, worsen
over time, bringing deteriorating health and higher costs in spite of DM
intervention.
■ Regression to the mean. This statistical property, whereby a person
measured at an extreme (such as high utilization cost) will tend to
move closer to the population average at next measurement, is clearly
illustrated in DM populations.
■ External variables. Events unrelated to the PDM program, such as
availability of a new clinical therapy, passage of a legislative coverage
Demonstrating sav-
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mandate, a recession, or problems in the patient’s family, may have a
substantial impact on its performance.
Even more problematic than a before-and-after cost comparison are at-
tempts to establish what expected cost trends would have been in the
absence of DM intervention. However, the observer must infer that meth-
odologies adequate to satisfy plan sponsors are devised, as PDM con-
tracts continue to be signed.
PARTICIPANT PERSPECTIVES
Consumers
An effective PDM program requires that potential members be screened
with respect to the target disease(s). A starting point is an individual
health assessment instrument. Some PDM programs offer incentives both
to employers (such as a reduction in the cost trend calculation when a
participation threshold is achieved) and to employees (such as a small
financial reward) to encourage completion of health assessments. Re-
wards may also be offered for agreeing to participate in the PDM pro-
gram; for example, one insurer waives some prescription drug
copayments for PDM participants.
A major component in the PDM strategy is patient education and self-
management. A PDM program participant may receive written materi-
als, have access to a nurse call line, receive regular telephone calls from a
nurse, or be placed in an electronic communication loop. An interesting
example of the latter is the talking scale issued to CHF patients by several
health plans. When the patient weighs in each day, the scale asks several
questions about symptoms and compliance with diet and exercise guide-
lines; responses are electronically transmitted to plan records. One plan
sponsor, pointing to better health outcomes by patients with scales, ob-
served that the improvement might well consist in patients’ complying
because “Big Brother is watching.” It is difficult to know what element(s)
of self-care interventions—the extra attention, the reminders, the train-
ing, the Big Brother effect, or something else—have the most impact.
Even with training and monitoring, PDM managers have found, adher-
ence to a care regimen on the part of patients is still a concern. LifeMasters
Supported Self-Care chief executive Christobel Selecky has proposed that
insurers grant a premium rebate to participants who abide by their care
plans for a specified period. Patients with dementia or other cognitive
disability obviously represent a particular challenge in this area.
Evidence on consumer response to PDM tends to be anecdotal or
assumptive (that is, of course people like attention and better health and
knowing they have somewhere to turn for help). While health plans may
conduct their own consumer satisfaction surveys, PDM as an industry
has yet to develop a standard satisfaction instrument, analogous to CAHPS
A major component in
the PDM strategy is
patient education and
self-management.
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(the widely used Consumer Assessment of Health Plans Survey), that
would permit cross-program comparisons.
Physicians
The decision to establish a PDM program is usually made by a health
plan or an employer. Identification and notification of participants’ phy-
sicians comes later in the process. Most PDM programs require the en-
rollee to identify a primary physician contact. The health plan may al-
ready have a relationship with that provider as an employee of a staff-
model HMO or a member in a preferred provider network, though out-
reach still may be required. For example, PDM contractor Health Man-
agement Corporation sends a short questionnaire to a new enrollee’s phy-
sician, seeking to capture the basics of his or her care plan for that patient.
Response rate varies by location, but in no case approaches 100 percent.
The preponderance of contact originates with case managers, who may
fax reminders of tests due to be performed or alerts of worsening or in-
deed alarming symptoms the patient is experiencing. In the Shah study
cited above, researchers noted that 52 physician notifications were gener-
ated by the monitoring service for 65 reported problems; physicians in-
tervened in 19 cases.18
PDM managers like to characterize their role as “physician extenders,”
selling themselves as a source of help to the busy practitioner. Anecdotal
evidence for the success of this approach is equivocal; the physician re-
sponse to PDM seems to range from gratitude to repugnance. For the
individual physician, response may depend on the degree to which he or
she has been involved in the development and use of the PDM approach
or the chronic care model. If dealing with a case manager as well as a
patient is an obligation imposed on the physician by a health plan, the
first impression well may be negative. As one physician noted, “It’s an-
other layer, more second-guessing.” Another used the verb “pestering.”
The pestered feeling may be exacerbated if among a physician’s patients
are enrollees in a number of different PDM programs.
On the positive side, some physicians see PDM as a means of delivering
to their chronically ill patients self-care support that they themselves are
not positioned to supply. Aware of the tensions, DMOs report that they
are exploring innovative ways of working with physicians, streamlining
communications, and offering incentives such as a management fee. The
Geisinger Health Plan places its own nurse-employees in primary care
physicians’ offices, where among their responsibilities is PDM patient
education and monitoring.
PDM IN MEDICAID AND SAFETY NET PROGRAMS
The Kaiser Commission on Medicaid and the Uninsured reported that 20
states had disease management/case management programs in 2002, with
Some physicians see
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an additional 6 signaling an intention to adopt new programs during
the fiscal year.19 As in the private sector, state programs are a mixture of
vendor contracts and in-house projects. States have found that PDM is
particularly compatible with primary care case management (PCCM)
systems already in place, as both PDM and PCCM are designed to fos-
ter care coordination, preventive services, and beneficiary support.
Florida’s pioneer PDM program might be viewed as a mirror of the
industry’s growing pains. Directed by the state legislature in 1997 to de-
velop a PDM program, initially for beneficiaries diagnosed with diabe-
tes, hemophilia, asthma, and HIV/AIDS, the state’s Agency for Health
Care Administration (ACHA) awarded contracts to separate DMOs for
each disease. While the agency seemed to feel that this would allow the
testing of several models simultaneously, the design as well as subse-
quent performance came in for considerable criticism. In May 2001, the
Florida legislature’s Office of Program Policy Analysis and Government
Accountability (OPPAGA) issued a report charging that
■ PDM services were not available for some diseases in all areas of the
state.
■ The agency was unable to prove the program had generated savings,
and had failed to include in DMO contracts an explicit methodology for
doing so.
■ Provider support and participation were limited.
■ Disease-specific contracts did not adequately address the holistic
health care needs of chronically ill beneficiaries.20
The legislature went on to adopt a preferred drug list and to direct
ACHA to negotiate supplemental rebates with pharmaceutical compa-
nies that wished to place products on the list. Permitted in lieu of cash
rebates were additional services, such as disease management programs.
ACHA eventually entered into agreements with two manufacturers for
disease management programs with savings guarantees. (OPPAGA has
been, if possible, even more critical of this arrangement and recently
called for the programs’ repeal.)
Other states have also chosen pharmaceutical management as their PDM
focus, acknowledging the role that rising drug costs have played in Med-
icaid budget hikes. Such programs are readily available from manufac-
turers and PBMs, and they are easy to administer and low-cost or even
free to taxpayers. Critics continue to hold that drug manufacturers use
PDM simply as a carrot to boost sales of their products.
A number of states have entered into multiple-disease arrangements with
DMOs. For example, Washington contracts with McKesson for asthma,
CHF, and diabetes management. Fees are at risk, 80 percent based on the
cost savings guarantee and 20 percent based on improvements in clinical
indicators. In some cases, health plans have taken the lead in developing
disease management programs for a Medicaid population. Neighborhood
State PDM programs
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Health Plan in Boston achieved a dramatic reduction in HIV/AIDS costs,
accompanied by improved health status, by sending nurses and outreach
workers into the community to provide training and support to Medic-
aid beneficiaries with the disease.
State-developed programs have had a mixture of outcomes. The Vir-
ginia Health Outcomes Partnership, another pioneering effort, aimed to
help physicians in a PCCM program manage asthma for Medicaid ben-
eficiaries. Evaluators calculated that, net of increased asthma drug costs,
the state saved $659 per physician trained.21 However, the state eventu-
ally opted instead for an outsourced PDM model focused on pharma-
ceutical management that was simpler and cheaper to administer.22 North
Carolina also began with an asthma add-on to its PCCM program, later
adding diabetes as well. State officials report success in terms of both
clinical indicators and cost. Administration builds on existing PCCM
mechanisms; primary care doctors, already paid a per member per month
fee for PCCM, receive an additional increment for disease management.
While establishing an expenditure baseline on which to calculate sav-
ings remains a challenge, the fact that savings guarantees and cost data
are in the public domain makes evaluation of Medicaid PDM programs
somewhat less arcane than evaluation of commercial programs. The state
of Washington’s savings guarantee requirements have been detailed in
presentations by Medical Assistance Administration officials.23 Christobel
Selecky has testified that LifeMasters’ CHF program in northern Florida
produced $3 million in savings to the state in its first year of operation.24
The U.S. Department of Health and Human Services’ (DHHS’) Bureau of
Primary Care has implemented disease management programs in its net-
work of community health centers (CHCs). As part of its Health Dispari-
ties Initiative, the bureau has collaborated with the Institute for Healthcare
Improvement to train coordinators from five geographic clusters in chronic
illness care. In 2002, 371 CHCs had chronic care projects in diabetes, car-
diovascular disease, asthma, or depression.25
PDM IN MEDICARE
Beneficiaries with certain chronic diseases account for a disproportionate
share of Medicare expenditures. Lawmakers are recognizing the need to
coordinate the often fragmented care Medicare beneficiaries receive for
both quality and cost reasons.
Many Medicare+Choice contractors already have PDM programs in place.
For example, Anthem Blue Cross Blue Shield developed PDM programs
in CHF and coronary artery disease in 1999, as well as adapting existing
case management programs in diabetes and asthma. On the fee-for-ser-
vice side, QIOs continue to work with providers on quality-improvement
projects around various chronic diseases. In an assessment of such projects
in all 50 states, Stephen F. Jencks and colleagues documented that the
Beneficiaries with cer-
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median state’s performance improved on 20 of 22 performance indica-
tors between the 1998–1999 baseline and a 2000–2001 follow-up.26 In ad-
dition, CMS has undertaken a number of demonstration projects to look
at various facets of care management.
The Omnibus Budget Reconciliation Act of 1990 mandated demonstra-
tions to provide case management services to Medicare beneficiaries with
selected catastrophic illnesses, particularly those associated with high
costs. Three demonstrations ensued, carried out by an insurer, a Peer Re-
view Organization, and a tertiary-care teaching hospital. Evaluators found
that none had much impact on either health behaviors (such as self-man-
agement and symptom control) or Medicare costs.27 The primary reason
they identified for the ineffectuality was that case managers received little
or no cooperation from the clients’ physicians.
Currently underway is a coordinated care demonstration called for in the
Balanced Budget Act of 1997. Sixteen organizations have undertaken
projects to provide case management and disease management services
to Medicare fee-for-service beneficiaries with chronic conditions. CMS
has said in testimony that the demonstration is designed to test “whether
coordinated care programs can improve medical treatment plans, reduce
avoidable hospital admissions, and promote other desirable outcomes.”28
Projects that offer such improvements and prove cost-effective as well
may be allowed to continue beyond the initial demonstration period.
A second demonstration (this one required by the Medicare, Medicaid,
and SCHIP Benefits Improvement and Protection Act of 2000) is designed
to show whether providing disease management services to Medicare
beneficiaries with diabetes, CHF, or coronary heart disease can produce
better health outcomes without increasing program costs. A unique fea-
ture of this demonstration is that Medicare will reimburse DMOs for their
enrolled patients’ prescription drugs.
Aimed at physician groups, a third demonstration seeks “to encourage
coordination of Part A and Part B services, reward physicians for improv-
ing beneficiary health outcomes, and promote efficiency through admin-
istrative structure and process.”29 Participating physicians will be paid
on a fee-for-service basis but be eligible for bonus payments based on
patient outcomes. Notice of still another demonstration was published in
the Federal Register on February 28; this one will test disease management
under capitated payment.
Still in the works is a more broadly based demonstration of disease man-
agement in fee-for-service Medicare. While the Medicare population is
aptly suited for PDM, some Medicare policies are not so accommodating.
For example, Medicare is not currently authorized to pay providers a
quality-based differential or to pay an add-on fee to physicians willing to
undertake PDM. The methodological challenges of documenting savings
remain. The budget neutrality requirements normally imposed by au-
thorizing legislation may be a sticking point if measured in the short term.
CMS has undertaken
a number of demon-
stration projects to
look at various facets
of care management.
14
NHPF Issue Brief No.791 / May 16, 2003
Would PDM be considered a covered benefit or should it be regarded
as a method of delivering benefits already covered?
A question that nags some policymakers is how disease management
can operate successfully in the absence of a drug benefit. PDM advo-
cates respond that this is not a disease management issue; in effect, the
entire practice of medicine operates in the absence of a drug benefit
under current law. As DMOs would not be the only health care provid-
ers to welcome Medicare coverage of prescription drugs, so they are
not the only providers to continue to encourage prescription compli-
ance while drugs are financed by the patient or a Medigap plan.
Drugs are only part of a larger coverage issue. Many items and ser-
vices routinely covered by commercial health plans are not paid for by
Medicare. How can a PDM program be expected to increase beneficia-
ries’ compliance with regimens that include items or services not cov-
ered by insurance?
A number of design and definition challenges face proponents of PDM
in Medicare. For example, which conditions will be targeted? What will
constitute core services? On what criteria will a program be evaluated?
It may be that many of these challenges can be met in the demonstration
process. It may be that the incorporation of PDM should be considered in
concert with broader Medicare reform proposals. It may be that more
research and more transparency are needed to determine whether PDM
can be moved from the “promising” category to the “proved.” Given the
growing burden of chronic care, however, it seems appropriate that Medi-
care be part of the quest for definitive answers.
CONCLUSION
Research on PDM generally concurs that such programs can improve the
quality of care that people receive. Evidence that PDM can save money is
most often presented in the form of reduced costs associated with hospi-
talization; there has been little public attention to total savings net of PDM
intervention costs. Campaigns and demonstrations are underway to bol-
ster the clinical and budgetary case for PDM. If successful, PDM’s accom-
plishment raises questions of another order: does the societal will exist to
pay for improvements in clinical quality, health, and quality of life on a
broad scale? And is DHHS willing to take the lead?
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